Dermapharm Holding SE

DMPHF

DMPHFDermapharm Holding SE

Other OTC

42.68

USD

- -

3.47EPS

12.30P/E

2.30BMarket Cap

May 15Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

Dermapharm Holding SE

DMPHF

(Other OTC)

Recent

price

42.68

P/E

ratio

12.3

div

yld

4.68%

ROIC.AI

Legends:

Stock price

Beta (1.0 Market)

% total return 09/18

Stock

S&P500

- -

26.92

- -

27.56

- -

87.12

2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	TTM
- -	7.27	7.15	8.9	9.35	10.72	13.02	14.74	17.51	19.03	21.09	20.99	Revenue per Share
- -	- -	0.24	1.54	1.56	1.41	1.43	1.59	3.89	2.49	1.16	1.54	Basic EPS, GAAP
- -	0.48	0.47	1.18	0.15	2.49	1.01	1.68	3.51	4.63	3.3	2.7	Free Cash Flow per Basic Share
- -	0.1	- -	- -	- -	- -	0.77	0.8	0.88	2.17	1.05	- -	Dividend per Share
- -	0.56	0.76	1.15	0.52	2.9	3.58	4.29	7.28	7.6	7.82	8.06	Book Value per Share
- -	-1.1	-0.74	-0.53	-1.69	0.22	-3.92	-4.44	-1.11	-0.81	-10.74	-10.21	Tangible Book Value per Share
- -	54	54	50	50	53	54	54	54	54	54	54	Basic Weighted Avg Shares
- -	391	385	444	467	572	701	794	943	1,025	1,135	1,132	Sales/Revenue/Turnover
- -	11.3	17.58	19.33	19.44	18.87	17.08	18.3	30.44	23.62	15.86	16.64	Operating Margin (%)
- -	18	15	14	16	30	48	47	55	95	102	95	Depreciation Expense
- -	- -	13	77	78	75	77	86	210	134	62	83	Net Income, GAAP
- -	6.32	5.28	7.09	11.68	27.83	29.3	31.41	28.7	38.69	42.89	37.71	Effective Tax Rate (%)
- -	-0.02	3.3	17.32	16.64	13.16	11.01	10.81	22.23	13.1	5.49	7.34	Profit Margin (%)
13	72	81	42	112	225	251	267	364	316	236	256	Working Capital
101	162	151	97	222	233	543	581	575	512	964	- -	LT Debt
41	34	44	61	74	256	284	325	500	532	545	556	Total Equity
- -	19.88	28.79	35.08	28.38	16.92	11.76	11.09	19.63	12.91	7.11	10.03	Return on Invested Capital (%)
- -	4.57	10.51	38.55	33.31	21.46	13.76	11.56	23.86	15.09	7.86	12.72	Return on Capital (%)
- -	-0.19	35.9	156.47	186.43	83.4	44.4	40.5	67.31	33.52	15.02	19.93	Return on Common Equity (%)

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	- -	14.79%	10.79%
Net Income, GAAP	- -	13.68%	-53.54%
Free Cash Flow	- -	24.01%	-28.71%
Total Cash Common Dividend	- -	9,214.44%	-51.61%
Total Equity	40.65%	17.61%	2.36%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Business: Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology primarily under the Dekristol, Dekristolvit, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; Momekort, a nasal spray used to treat allergy symptoms; and Azedil, a nasal spray or eye drop. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.

	Dec'23	Mar'24	Jun'24
ST Debt	116	- -	- -
LT Borrowings	951	- -	- -
LT Finance Leases	13	- -	- -
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	54	54	54
Market Capitalization	- -	- -	- -

2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	TTM
- -	7.27	7.15	8.9	9.35	10.72	13.02	14.74	17.51	19.03	21.09	20.99	Revenue per Share
- -	- -	0.24	1.54	1.56	1.41	1.43	1.59	3.89	2.49	1.16	1.54	Basic EPS, GAAP
- -	0.48	0.47	1.18	0.15	2.49	1.01	1.68	3.51	4.63	3.3	2.7	Free Cash Flow per Basic Share
- -	0.1	- -	- -	- -	- -	0.77	0.8	0.88	2.17	1.05	- -	Dividend per Share
- -	0.56	0.76	1.15	0.52	2.9	3.58	4.29	7.28	7.6	7.82	8.06	Book Value per Share
- -	-1.1	-0.74	-0.53	-1.69	0.22	-3.92	-4.44	-1.11	-0.81	-10.74	-10.21	Tangible Book Value per Share
- -	54	54	50	50	53	54	54	54	54	54	54	Basic Weighted Avg Shares
- -	391	385	444	467	572	701	794	943	1,025	1,135	1,132	Sales/Revenue/Turnover
- -	11.3	17.58	19.33	19.44	18.87	17.08	18.3	30.44	23.62	15.86	16.64	Operating Margin (%)
- -	18	15	14	16	30	48	47	55	95	102	95	Depreciation Expense
- -	- -	13	77	78	75	77	86	210	134	62	83	Net Income, GAAP
- -	6.32	5.28	7.09	11.68	27.83	29.3	31.41	28.7	38.69	42.89	37.71	Effective Tax Rate (%)
- -	-0.02	3.3	17.32	16.64	13.16	11.01	10.81	22.23	13.1	5.49	7.34	Profit Margin (%)
13	72	81	42	112	225	251	267	364	316	236	256	Working Capital
101	162	151	97	222	233	543	581	575	512	964	- -	LT Debt
41	34	44	61	74	256	284	325	500	532	545	556	Total Equity
- -	19.88	28.79	35.08	28.38	16.92	11.76	11.09	19.63	12.91	7.11	10.03	Return on Invested Capital (%)
- -	4.57	10.51	38.55	33.31	21.46	13.76	11.56	23.86	15.09	7.86	12.72	Return on Capital (%)
- -	-0.19	35.9	156.47	186.43	83.4	44.4	40.5	67.31	33.52	15.02	19.93	Return on Common Equity (%)

	Dec'23	Mar'24	Jun'24
Total Current Assets	630	649	695
Accounts Receivable, Net	91	125	112
Cash, Cash Equivalents & STI	160	121	172
Inventories	317	337	351
Total Current Liabilities	394	414	440
Payables & Accruals	- -	- -	- -
ST Debt	116	- -	- -
Deferred Revenue	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	232	239	263	291	1,025
2023	319	263	284	269	1,135
2024	299	280	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	0.69	0.27	- -	- -	2.49
2023	0.92	-0.17	- -	- -	1.16
2024	0.81	0.32	- -	- -	- -

Dermapharm Holding SE

Growth Rates

(avg. rate of change)

Capital Structure

Growth Rates

(avg. rate of change)

Working Capital

Quarterly Earnings Per Share

Year

Quarterly Revenue

Year

Quarterly Dividends Per Share

Year